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Abstract
BACKGROUND: Advanced colon cancer is associated with weight loss and decreased survival. Studies suggest
that angiotensin and β-adrenergic blockade decrease colon cancer progression and ameliorate weight loss. This
study aims to determine whether exposure to β-adrenoceptor blockers (BBs), angiotensin-converting enzyme
inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) is associated with decreased mortality, tumor progres-
sion, number of hospitalizations, or weight loss in colorectal cancer. METHODS: Retrospective chart review
included patients with advanced colorectal cancer. Survival, stage, hospitalization, cancer progression, cancer
treatment, and body weight history were collected. RESULTS: Two hundred sixty-two of 425 new stage III to IV
colorectal cancer cases reviewed met the study criteria. Those exposed to ACEI/ARB, BB, or both were more likely
to have diabetes, hypertension, and stage III colorectal cancer. Adjusting for age, presence of hypertension and
diabetes, and stage, ACEI/ARB + BB exposure was associated with decreased mortality compared to unexposed
individuals [hazard ratio (HR) = 0.5, confidence interval (CI) = 0.29-0.85; Cox regression, P = .01]. Fewer total and
cancer-related hospitalizations and decreased cancer progression in the ACEI/ARB + BB group versus the un-
exposed group (HR = 0.59, CI = 0.36-0.99, P = .047) were seen. Exposure did not affect weight changes; further-
more, body weight changes from both prediagnosis and at diagnosis to 6, 12, 18, and 24 months postdiagnosis
predicted survival. CONCLUSIONS:We have observed an association between exposure to a combination of ACEI/
ARB + BB and increased survival, decreased hospitalizations, and decreased tumor progression in advanced
colorectal cancer. Future studies will be needed to replicate these results and generalize them to broader popula-
tions. Determination of causality will require a randomized controlled trial.
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Introduction
Colorectal cancer is the third most prevalent cancer in America with
more than 143,000 people newly diagnosed with this disease each
year. Although several treatments are available for advanced colo-
rectal cancer, novel therapies are needed, given that this cancer is
one of the leading causes of death in the western world and it usually
takes a toll on these patients’ quality of life [1].
Recent studies suggest that angiotensin-converting enzyme inhibi-
tors (ACEIs) and angiotensin receptor blockers (ARBs) may modulate
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the development and progression of cancer [2]. ACEIs reduce the
production of angiotensin II, whereas ARBs selectively block the
activation of angiotensin II type 1 receptors. Both result in a suppres-
sion of the renin-angiotensin system. Angiotensin II, through activation
of vascular endothelial growth factor (VEGF) and VEGF receptor 2
expression in endothelial cells, stimulates neovascularization [3–5].
The angiotensin II type 2 receptor is a G protein–coupled receptor that
regulates signal transducer and activator of transcription 3 (STAT3)
[6]. These heterotrimeric G proteins and STAT3 have recently been
established as novel therapeutic targets for both lung and colon
cancers [7]. Angiotensin II also acts as an antiapoptotic agent and
growth factor, stimulating cell replication through the epidermal
growth factor receptor transactivation/extracellular signal-regulated
kinase (ERK) signaling pathway. In vitro, the growth of cultured cancer
cells is retarded by ACEI [8]. Moreover, they inhibit angiogenesis and
growth of induced cancer in rats [9,10]. There are also data to suggest
that blocking angiotensin II may decrease muscle proteolysis, prevent
cachexia, and improve the host’s function [11].
The β-adrenergic receptor has also been implicated as a potential
therapeutic target for cancer. Circulating norepinephrine and epineph-
rine bind to β-adrenergic receptors and subsequently stimulate macro-
phages and cancer cells to produce angiogenic factors, including VEGF
[12]. β-Adrenoceptor blockers (BBs) are believed to downregulate the
rapidly accelerated fibrosarcoma (RAF)–mitogen-activated protein
kinase (MAPK) pathway and, consequently, inhibit angiogenesis. More-
over, studies have shown that blockade of adrenergic activity and sub-
sequent decline in resting energy expenditure (REE) in tumor-bearing
animals and patients with cancer may prevent cancer cachexia.
Given that a large number of individuals receive ACEI, ARB, or
BB as part of the treatment for hypertension, we sought to determine
whether exposure to these agents is associated with decreased tumor
progression, mortality, weight loss, or number of hospitalizations in
patients with advanced colorectal cancer.
Materials and Methods
This was a retrospective chart review of patients diagnosed with
advanced colorectal cancer at the Michael E. DeBakey Veterans Affairs
(VA) Medical Center (Houston, TX) between January 2000 and
July 2009. Inclusion criteria were men and women older than 18 years
with stage III and IV colorectal cancer. Exclusion criteria were
medical conditions associated with weight loss or that would benefit
from BB and/or ACEI/ARB for other reasons, including New York
Heart Association class III or IV congestive heart failure (CHF), end-
stage liver disease or liver function tests more than three times the
normal limits, renal failure defined with creatinine ≥ 3 mg/dl, hyper-
thyroidism, or human immunodeficiency virus infection. Other con-
ditions that would affect weight, such as significant edema, use of
anabolic agents such as testosterone, growth hormone, orexigenic
agents (i.e., Megestrol), or research medications were excluded. Pa-
tients with known medication noncompliance were not included in
this study.
Data collected included survival, hospitalization, gender, cancer
progression, cancer treatment, body weight history (at 6-12 months
prediagnosis, at time of diagnosis, and every 6 months postdiagnosis
for 24 months), albumin, creatinine, medications, and stage. All
survival data were collected until 15 December 2011 or until death,
whichever occurred first. Subjects were followed for a maximum of
4364 days. Hospitalization and death events were categorized as
cancer related or not cancer related. To account for differences in time
at risk for being hospitalized, we calculated total hospitalization and
cancer-related hospitalization ratios as follows: Total (or cancer-related)
hospitalizations/years survived.
Exposure groups for ACEI, ARB, and BB were defined as pre-
scription use≥6 months per any year in the observation period (1 year
before cancer diagnosis to 3 years postdiagnosis). A secondary analysis
was also performed, categorizing subjects on the basis of exposure to
these drugs on the year before diagnosis to account for a potential
immortal time bias [13] and including only subjects that survived at
least 6 months after diagnosis to account for the potential influence
of medications being withdrawn before death. Compliance with medi-
cations was established by prescription use for≥6 months with patient-
initiated medication refills. Cancer progression was determined by
increasing tumor size on serial imaging or the oncologist’s documenta-
tion in progress notes. ACEIs and ARBs were combined into one
group because there were no differences in relevant outcomes between
the two groups and because of the similar mechanism of action.
Individuals were categorized into one of these four mutually exclusive
exposure groups: 1) unexposed to BB, ACEI, or ARB (control group),
2) exposed to ACEI and/or ARB only, 3) exposed to BB only, or 4)
exposed to both ACEI/ARB and BB.
All statistical analyses were performed using SPSS software (SPSS
17.0; IBM, Somers, NY). Variables were summarized descriptively
by group using N , mean, and standard error or by median and inter-
quartile range for continuous variables and by frequencies (%) for
nominal or ordinal variables. Analysis of variance (ANOVA) was
used to analyze normally distributed continuous variables, and non-
parametric tests were used for non-normally distributed variables.
Statistical comparisons for categorical data were performed using
the Fisher exact test or χ2 test. Statistical significance was assigned
to each comparison for P < .05, and appropriate post hoc tests were
used when needed during ANOVA. It was anticipated that cancer
stage may be highly associated with survival. The association between
drug exposure or weight change and survival and tumor progression
was measured by a Cox proportional hazards model to determine
which variables, in addition to cancer stage, were significant predictors
of mortality or progression of disease. The measure of association was
given by the hazard ratio (HR) and confidence intervals (CIs), with
time to event (death or progression) being the outcome of interest.
For preliminary stepwise regression analyses used to determine signif-
icant cofactors for predicting survival or weight change percent, α for
excluded variables was set at 0.10.
Role of the Funding Source
The Department of Veterans Affairs and the National Institutes of
Health did not play a role in study design, in the collection, analysis, and
interpretation of data, in the writing of the report, and in the decision
to submit the paper for publication.
Results
Of the 425 charts reviewed, 163 patients were excluded (Figure 1).
Of the 262 patients that met the criteria, patients that were exposed
to ACEI/ARB, BB, or both were most likely to have diabetes, hyper-
tension, and stage III colorectal cancer. This is likely due to the fact
that these medications are used to treat hypertension and compli-
cations of diabetes. Furthermore, there may be a physician bias to
not prescribe these medications to their more ill, stage IV, patients.
Diabetes, hypertension, and stage were included as covariates in all
analyses. Body weight was significantly lower for the unexposed
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group than for the exposed group. There was no significant difference
in age, gender, chemotherapy regimen, or radiation therapy between
groups (Table 1). The study patients were predominantly elderly,
white males, as expected in a VA hospital setting.
Exposure to ACEI, ARB, or BB and Survival
Exposure to ACEI/ARB + BB combination was associated with
decreased mortality compared to unexposed individuals even after
adjusting for age, presence of diabetes and hypertension, and stage
(Table 2 and Figure 2). Exposure to BB or ACEI/ARB alone did
not significantly improve survival compared to the unexposed group.
The majority of deaths in all groups was cancer related [100% (109
of 109) in unexposed, 94.4% (34 of 36) in ACEI/ARB only, 100%
(22 of 22) in BB only, and 100% (16 of 16) in ACEI/ARB + BB].
The survival benefit of exposure to ACEI/ARB + BB combination
persisted on the secondary analysis performed, categorizing subjects
on the basis of exposure to these drugs on the year before diagnosis
and including only subjects that survived at least 6 months after
diagnosis [odds ratio = 0.27 (CI = 0.09-0.85) compared to unexposed,
P = .03].
Exposure to ACEI, ARB, or BB and Tumor Progression
and Hospitalizations
Exposure to BB or ACEI/ARB alone did not significantly change
the rate of tumor progression compared to the unexposed group.
However, subjects receiving ACEI/ARB + BB combination had
decreased risk of tumor progression. Tumor progression was not
predicted by hypertension, but it was predicted by the presence of
diabetes. Nevertheless, exposure to ACEI/ARB and BB remained a
significant predictor of tumor progression even after adjusting for
the presence of diabetes and stage (HR = 0.59, CI = 0.36-0.99, P =
.05; Figures 3 and 4).
Hospitalizations were evaluated as the ratio of number of hospital-
izations (total or cancer related) per year survived and were analyzed
by ANOVA adjusting for multiple comparisons. Diabetes and hyper-
tension were not found to be associated with these outcomes on re-
gression analyses. There was a significant decrease in total (P = .004)
as well as cancer-related (P = .006) hospitalizations in the ACEI/ARB +
BB group compared to the unexposed group (Figure 5). BBs or ACEI/
ARB alone did not affect the rate of hospitalizations.
Exposure to ACEI, ARB, or BB and Weight
Body weights at 6 to 12 months prediagnosis and at the time of
diagnosis were lower for the unexposed group compared to the
ACEI/ARB and BB + ACEI/ARB groups (Table 1). Hence, body
weights were analyzed as change from baseline to account for these
differences. Body weight changes from 6 to 12 months prediagnosis
or at the time of diagnosis to 6, 12, 18, or 24 months postdiagnosis
were not significantly different between groups (Figure 6). Neither
diabetes nor hypertension was associated with weight change from
prediagnosis or baseline to all other time points.
Body Weight and Survival
Body weights at 6 to 12 months prediagnosis or at the time of
diagnosis were not predictive of survival on Cox regression analysis
adjusted for stage (HR = 0.99, CI = 0.97-1.03, P = .84 and HR =
0.99, CI = 0.96-0.10, P = .42, respectively). Body weight changes
from 6 to 12 months prediagnosis to 6, 12, 18, and 24 months post-
diagnosis were significant predictors of survival even after adjusting
Table 1. Baseline Characteristics by Exposure Groups.
Unexposed (n = 141) ACEI/ARB Only (n = 52) BB Only (n = 32) ACEI/ARB + BB (n = 39) P Value
Male sex 97.1% (137) 96.2% (50) 93.8% (30) 100% (39) .385
Age 62.98 (0·93) 66.48 (1.34) 66.53 (2.07) 65.55 (1.62) .110
Stage III 39.0% (55) 59.6% (31)* 57.6% (16)* 69.2% (27)* .002
White race 64.5% (91) 65.9% (34) 53.1% (17) 51.2% (20) .649
HTN 45.3% (64) 84.6% (44)* 71.9% (23)* 94.8% (37)* <.01
DM 19.1% (27) 32.7% (17)* 21.9% (7)* 43.5% (17)* .008
CHF 3.5% (5) 0% (0) 3.1% (1) 5.1% (2) .495
Body weight (kg) 79.19 (1.72) 88.11 (2.39)* 87.13 (3·40)* 94.83 (3.68)* <.01
BMI (kg/m2) 25.4 (0.51) 27.6 (0.70)* 28.4 (1.19)* 29.5 (1.13)* .001
Albumin 3.20 (0.05) 3.29 (0.09) 3.20 (0.09) 3.38 (0.08) .412
Chemo 69.5% (98) 67.3% (35) 78.1% (25) 76.9% (30) .099
XRT 26.9% (38) 29.4% (15) 28.1% (9) 17.9% (7) .653
Categorical variables are shown as percentage (n). Continuous variables are shown as means (SE). P values were obtained using χ2 test or ANOVA with Tukey post hoc test. HTN, hypertension;
DM, diabetes mellitus; BMI, bodymass index; Chemo, chemotherapy; XRT, radiation therapy; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-adrenoceptor blocker.
*P < .05 compared to unexposed group.
Figure 1. Overview of study selection. CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; tx, treatment.
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for stage (Figure 7). Moreover, body weight changes from diag-
nosis to 6, 12, 18, and 24 months postdiagnosis were also signifi-
cant predictors of survival after adjusting for stage (HR = 0.97,
CI = 0.95-0.99, P = .01; HR = 0.97, CI = 0.95-0.99, P = .001;
HR = 0.87, CI = 0.81-0.94, P = .001; HR = 0.82, CI = 0.76-0.88,
P < .001, respectively).
Discussion
Our data suggest that exposure to a combination of BB and ACEI/
ARB is associated with decreased tumor progression, decreased hos-
pitalizations, and increased survival in patients with advanced colo-
rectal cancer even after adjusting for cancer stage. This is potentially
very relevant because this disease is very prevalent and it usually affects
quality of life and survival greatly in these patients.
Several mechanisms have been proposed for angiotensin or β-
adrenergic receptor blockade to improve these outcomes in patients
with colon cancer. BBs and ACEI/ARB are associated with decreased
Figure 2. Exposure and survival—HR compared to unexposed
subjects. ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; BB, β-adrenoceptor blocker.
Figure 3. Exposure and tumor progression. ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BB, β-adrenoceptor blocker. P value was obtained using χ2 test,
comparing ACEI/ARB + BB to unexposed group.
Table 2. Survival by Exposure.
Group Median (Days) Interquartile Range (25%-75%)
Unexposed 695 192-1416
ACEI/ARB 1041 230-1787
BB 1056 326-1504
ACEI/ARB + BB 1341* 997-1941
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-adrenoceptor
blocker; P value was calculated by median test.
*P < .05 compared to unexposed group.
Figure 4. Exposure and tumor progression—HR compared to un-
exposed subjects. ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; BB, β-adrenoceptor blocker.
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mortality in the setting of CHF [14,15]. Although it is possible that
the decrease in mortality was due to these well-known cardiovascular
effects, this is unlikely in this setting given that almost all deaths were
cancer related. In addition, angiotensin and β-adrenergic receptor
blockade are thought to have antiproliferative effects in tumors.
Angiotensin II mediates induction of VEGF, resulting in angiogenesis
[16,17]. Furthermore, it can activate multiple mitogenic signaling path-
ways, such as protein kinase C, phosphatidylinositol-3-kinase–protein
kinase B (PI3K-AKT), MAPK, and STAT3, leading to cancer pro-
liferation [18]. Yasumaru et al. showed that angiotensin II blockade
also enhances the antitumor effect of cycloxygenase-2 (COX-2) in-
hibitors through the insulin-like growth factor-1 (IGF-1) receptor
pathway [19]. Lastly, several groups have shown that angiotensin
blockade can mitigate the cardiac toxicity associated with some chemo-
therapy regimens, thereby enhancing tolerability of these drugs and
allowing more effective doses of these agents to be delivered [20].
Other reports are in agreement with our findings. For instance,
Lever and colleagues showed recently that long-term use of ACEI
Figure 5. Total and cancer-related hospitalizations. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BB, β-adrenoceptor blocker. P values were compared to unexposed. Hospitalization ratio was calculated as the ratio of number of
hospitalizations (total or cancer related) per year survived.
Figure 6. Exposure and weight change. BMI, body mass index; dx, diagnosis; mo, months; ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; BB, β-adrenoceptor blocker.
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can protect against certain types of cancers, including colorectal, lung,
and breast cancers. Compared with controls, the relative risk of
developing cancer was 0.72 (95% CI = 0.55-0.92) in that report
[21]. Long-term use of lisinopril has also been associated with decreased
incidence of advanced adenomatous colon polyps and decreased tumor
metastasis in non–small cell lung cancer [22].
BBs have also been considered as potential novel therapies for can-
cer. In 2004, a cohort study of 839 patients followed prospectively
for an average of 10 years showed a reduced cancer risk with BB
usage [23]. Furthermore, population-based studies have suggested that
inhibition of β2-adrenergic signaling pathway could reduce breast can-
cer progression and mortality [12]. In 2008, propranolol was shown
to inhibit the growth of hemangiomas [24] and the proliferation of
human umbilical vein endothelial cells [25]. These data suggest that
β-blockade results in inhibition of angiogenesis. It is hypothesized
that this is the result of down-regulation of VEGF and basic fibroblast
growth factor genes through the inhibition of the RAF-MAPK path-
way. Adrenaline directly stimulates colon cancer cell growth through
β-adrenoceptors [26] and has been shown to stimulate HT-29 cell
proliferation and expression of COX-2 and VEGF. This may be rele-
vant because COX-2 is overexpressed in colon cancer and may play a
role in cancer progression [27]. Animal experiments have shown that
carvedilol reduces the expression of hypoxia-inducible factor 1α, which
plays a major role in regulating tumor angiogenesis [28]. Moreover,
propranolol inhibits the secretion of matrix metalloproteinases, which
are significantly increased during tumor progression and thought to
play a key role in angiogenesis [29].
Increased cancer progression was noted in the unexposed group
compared to the ACEI/ARB + BB exposed group. Furthermore, when
observing the number of hospitalizations adjusted for the time sur-
vived, there was a clear decrease in total and cancer-related hospitaliza-
tions in the group exposed to ACEI/ARB + BB. These findings further
support the hypothesis that these agents have a beneficial effect in this
setting. The fact that the majority of the hospitalizations were cancer
related also suggests that the mechanisms mediating these effects were
cancer related rather than cardiovascular.
Moreover, ACEI/ARB and BBs may prevent cachexia in the set-
ting of cancer, and this could also contribute to their positive effect
on survival. ACEI/ARB inhibit muscle proteolysis through inhibition
of the suppressor of cytokine signaling-3 (SOCS3) pathway [11].
β-Blockade decreases REE and subsequently inhibits lipolysis [30].
Elevated REE in patients with cancer contributes to progressive weight
loss and is largely related to the increased adrenergic activity and sen-
sitivity. It is thought that this could be an adaptive response to sys-
temic inflammation and partial starvation. Previous studies have
shown a significant reduction in whole-body REE in patients with solid
tumors after 5 days of BB therapy [30]. Nevertheless, our data do not
support a role of angiotensin or β-adrenergic blockade in preventing
cachexia or muscle wasting given that we failed to show an association
between overall weight changes and exposure to these drugs. More
studies are needed to test this hypothesis directly.
Mortality was significantly decreased in the group exposed to both
drugs but not to the individual drugs. Given that these drugs work
through mechanisms that could be complementary (such as modifying
tumor vascularization through VEGF), there may be an additive effect
of these medications on survival. In addition, it is possible that a larger
sample size may have resulted in a significant difference in these indi-
vidual groups, although our data do not support this because the HRs
for tumor progression or survival were indistinguishable between the
BB or ACEI/ARB group and the unexposed group.
Body weights at prediagnosis and at diagnosis or weight loss his-
tory at the time of diagnosis was not predictive of survival; however,
changes in body weight from both prediagnosis or at diagnosis to all
time points were predictive. This is consistent with the work of several
groups including ours [31] showing the predictive value of weight
changes on survival in the setting of cancer. It was particularly inter-
esting to see how the predictive value of weight changes increased with
a longer follow-up. This suggests that clinicians should continue to
evaluate weight changes beyond the diagnostic stages and may use
these as a prognostic indicator.
Strengths of this study include the relatively homogeneous popu-
lation studied. The potential for confounding by factors such as socio-
economic status or gender is greatly decreased because patients within
the VA system are more likely to be males of similar socioeconomic
status and all subjects have access to the same level of care. In addi-
tion, all patients were treated by the same group of oncologists follow-
ing current guidelines of treatment. The long-term follow-up enabled
a sufficient number of cancer outcomes and accurate survival data to be
obtained. The clinical data were retrieved from the detailed electronic
medical record and, thus, not subject to recall bias.
Limitations of this study include the lack of female patients, given
the predominance of men in the VA system. In addition, the retrospec-
tive analysis of medical record data makes it difficult to determine causal-
ity of the associations found or to confirm medication compliance.
Nevertheless, within the VA system, medications are not mailed un-
less the patient requests them in person or by phone, increasing the
accuracy of our medical record system. Multiple other retrospective
studies relying on our VA electronic medical record have been pub-
lished [32]. We did not correlate mortality with drug frequency or
length of use. However, most individuals who are prescribed with
these drugs are likely to take them for long periods of time. While
there were significantly more patients with diabetes and hypertension
Figure 7.Weight change and survival—HR; predx, prediagnosis; DX,
diagnosis; mo, month.
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in the exposed groups, this would have likely resulted in an increased, not
decreased, mortality.
In summary, we show here that patients with advanced colon
cancer receiving ACEI/ARB and BBs have increased survival and
decreased tumor progression and hospitalization rate. Although the
mechanisms underlying these observations could not be elucidated
from this study, further studies may be warranted to determine if
angiotensin and/or adrenergic blockade will improve outcomes in
patients with advanced colon cancer.
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